Doravirine (DOR) + Rifapentine (RPT) + Isoniazid (INH)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Latent Tuberculosis
Conditions
Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use, Drug Interaction Potentiation
Trial Timeline
Apr 22, 2019 → May 20, 2019
NCT ID
NCT03886701About Doravirine (DOR) + Rifapentine (RPT) + Isoniazid (INH)
Doravirine (DOR) + Rifapentine (RPT) + Isoniazid (INH) is a phase 1 stage product being developed by Merck for Latent Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03886701. Target conditions include Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03886701 | Phase 1 | Completed |
Competing Products
2 competing products in Latent Tuberculosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NovoMix 30 + Tablet treatment | Novo Nordisk | Pre-clinical | 22 |
| Rifapentine + Isoniazid | Sanofi | Phase 1/2 | 40 |